Compare Page
GHRP-2 vs GHRP-6
Quick verdict: GHRP-2 vs GHRP-6 is a selectivity-versus-potency comparison within the same receptor class. Both are synthetic growth hormone secretagogues that activate the ghrelin receptor (GHS-R1a), but they sit at different points on the selectivity spectrum. GHRP-2 produces one of the strongest GH responses of any synthetic secretagogue with moderate off-target effects (appetite, cortisol, prolactin).[1] GHRP-6 produces slightly less potent GH release but with substantially stronger appetite stimulation and more pronounced cortisol and prolactin elevation — making it the least selective compound in the GHRP family.[1][2] The choice depends on whether maximal GH output or minimised side-effect burden is more important to the research question. For the cleanest selectivity profile in this class, see GHRP-2 vs Ipamorelin.
Read the full peptide profiles: GHRP-2. (Note: GHRP-6 does not have a dedicated profile page on this site.)
At a Glance: GHRP-2 vs GHRP-6
How They Work
GHRP-2 and GHRP-6 share the same primary mechanism: both are synthetic hexapeptides that activate the growth hormone secretagogue receptor (GHS-R1a, the ghrelin receptor) on anterior pituitary somatotroph cells, triggering pulsatile growth hormone release. Both also act at the hypothalamic level, stimulating endogenous GHRH release to create a dual-level amplification effect. The core pharmacology is identical — the differences lie in potency and off-target receptor activity.[1][2]
GHRP-2 produces a more potent and selective GH response. While it does elevate appetite, cortisol, and prolactin to some degree (making it less selective than ipamorelin), these effects are moderate and transient — cortisol typically returns to baseline within 60-90 minutes. The GH amplitude achieved with GHRP-2 is among the highest of any synthetic secretagogue, making it the compound of choice when maximal GH output is the primary endpoint.[1]
GHRP-6 activates the same receptor but with a broader activation profile that produces more pronounced off-target effects. The appetite stimulation with GHRP-6 is the strongest in the GHRP class — a direct consequence of its ghrelin-receptor activity in the hypothalamic arcuate nucleus. Cortisol and prolactin elevations are also more pronounced compared to GHRP-2. The GH response, while strong, is generally reported as slightly less potent than GHRP-2 at comparable concentrations.[1][2][3]
Evidence Comparison
Both GHRP-2 and GHRP-6 have been studied since the 1990s, giving them decades of published research. The foundational selectivity comparisons were established early: Raun et al. (1998) used GHRP-6 as the benchmark comparator when characterising ipamorelin’s selectivity advantage, documenting that GHRP-6 elevates cortisol, ACTH, and prolactin alongside GH — effects that ipamorelin avoids and that GHRP-2 shows to an intermediate degree.[1]
GHRP-2 has a somewhat deeper pharmacological characterisation in published literature, with more studies directly measuring its GH potency relative to other secretagogues. Sigalos & Pastuszak (2018) reviewed GH secretagogues as a class and confirmed that GHRP-2 sits between GHRP-6 (least selective) and ipamorelin (most selective) on the selectivity spectrum, with GH potency inversely correlated with selectivity across the class.[3]
Neither compound has been evaluated in large-scale clinical trials or received FDA approval. The evidence base for both is primarily pharmacological and preclinical, with limited human outcome data for specific endpoints like body composition or recovery. The class-level evidence for GH secretagogues is supportive of GH-axis activation benefits, but compound-specific clinical evidence is limited for both GHRP-2 and GHRP-6.
When Each Fits Better
GHRP-2 may be the stronger fit when:
- Maximal GH amplitude is the primary endpoint — GHRP-2 produces one of the strongest GH responses among synthetic secretagogues[1]
- Moderate appetite stimulation is acceptable — appetite effect is present but manageable
- A balance between potency and selectivity is desired — GHRP-2 sits in the middle of the GHRP selectivity spectrum
- Synergistic combination with GHRH-pathway compounds is planned — well-documented amplification with GHRH analogs[1][3]
GHRP-6 may be of greater interest when:
- Appetite stimulation is a desired effect — GHRP-6 produces the strongest orexigenic response in the class, relevant for caloric surplus research contexts
- Historical comparator data is needed — GHRP-6 was used as the standard benchmark in many early GH secretagogue studies[1]
- Cost or availability considerations favour GHRP-6
- The broader ghrelin-mimetic pharmacological profile is the subject of investigation
Head-to-Head
The GHRP-2 versus GHRP-6 comparison within the secretagogue class follows a consistent pattern: GHRP-2 offers better GH potency with a more manageable side-effect profile, while GHRP-6 offers somewhat lower GH output with more pronounced hormonal cross-talk. This pattern is well-established in comparative pharmacological literature and represents a genuine selectivity gradient within the GHRP family.[1][2]
The selectivity spectrum across the full GHRP/secretagogue class runs: ipamorelin (most selective) → GHRP-2 (moderate) → GHRP-6 (least selective). Each step down in selectivity generally corresponds to broader receptor activation, more appetite stimulation, greater cortisol elevation, and higher prolactin levels. The GH potency relationship is more complex — GHRP-2 appears to produce stronger GH responses than GHRP-6 despite being more selective, suggesting that raw GHSR affinity and GH-release potency don’t perfectly correlate with off-target effects.[1][3]
For most research contexts where GH secretagogue activity is desired, GHRP-2 offers a more favourable risk-benefit profile than GHRP-6 unless the appetite-stimulating effect is specifically desired. For the cleanest selectivity profile in the class, ipamorelin remains the reference compound. See GHRP-2 vs Ipamorelin for that comparison.
FAQ
Is GHRP-2 stronger than GHRP-6?
Yes, GHRP-2 generally produces a stronger GH response than GHRP-6 at comparable concentrations, while also having a more favourable selectivity profile (less cortisol, less prolactin, less appetite stimulation). This makes GHRP-2 the preferred compound in most research contexts where GH potency is the primary endpoint.[1][2]
Why does GHRP-6 stimulate appetite more than GHRP-2?
Both compounds activate the ghrelin receptor (GHS-R1a), which is expressed in the hypothalamic arcuate nucleus — the brain’s appetite regulation centre. GHRP-6 appears to have a broader activation profile at this receptor, producing stronger orexigenic (appetite-stimulating) signalling. This is an inherent pharmacological property rather than a dose-dependent effect.[1][2]
Can GHRP-2 or GHRP-6 be combined with GHRH analogs?
Yes, the pharmacological rationale is sound. GHRPs work through the GHS-R1a (ghrelin) pathway, while GHRH analogs like sermorelin and CJC-1295 work through the GHRH receptor. These are independent pathways on the same pituitary cell, and dual-pathway stimulation is theorised to produce synergistic GH release. This has been documented in neuroendocrine research, though dedicated combination outcome trials are limited.[1][3]
How do both compare to ipamorelin?
Ipamorelin is the most selective GH secretagogue — it produces dose-dependent GH release without elevating cortisol, ACTH, prolactin, or aldosterone.[1] Both GHRP-2 and GHRP-6 are less selective, with GHRP-6 having the most off-target effects. If selectivity is the priority, ipamorelin is the clear choice. If maximal GH amplitude matters more, GHRP-2 may be preferable. See GHRP-2 vs Ipamorelin.
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822.
- Bowers CY, et al. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 1991. PMID: 9467534.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207.
- Svensson J, et al. Effects on bone mineral content of growth hormone-releasing peptides. J Endocrinol. 2000;165(2):339-346. PMID: 10810296.
- Johansen PB, et al. Ipamorelin induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PMID: 10373343.